ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P58-23 Medicare Advantage Part B Step Therapy Program Expansion to Include Vyvgart and Ultomiris
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2023
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1301 - 1310 လၢ 4229 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
covid19-faq-11-18-2022.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP95-22 Minnesota Health Care Programs Operations Transition
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP94-22 Commercial Pharmacy Benefit Exclusion for Select Medications
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP93-22 MHCP Pharmacy Benefit Exclusion for Pedmark®, Rolvedon™, Skysona®, Spevigo®, and Xenpozyme™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP90-22 Provider Press: Q4 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP96-22 Update: Change to 2023 Cyber Insurance Requirement for Primary Care Clinic and Institutional Providers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP91-22 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective January 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP92-22 MHCP Pharmacy Benefit Exclusion for Cimerli™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2022